Pre- and postoperative chemotherapy including bevacizumab in potentially curable metastatic colorectal cancer: A multicenter, single-arm phase II trial--Results of ASSO LM1.

e14032 Background: Patients with colorectal cancer (CRC) and liver metastases may benefit from perioperative chemotherapy and disease resection. Best treatment sequence, length and combination still needs to be determined. We evaluated bevacizumab and XELOX in a multicenter approach. Methods: Patients with liver metastases from CRC potentially curable by resection were eligible for this trial. Patients received bevacizumab 5 mg/kg (day 1), oxaliplatin 85 mg/m2 (day 1) and capecitabine 3,000 mg/m2/day (days 1–7) of a 2-week cycle, for six cycles. The sixth cycle did not include bevacizumab, resulting in 5 weeks between the last bevacizumab dose and surgery. Therapy with bevacizumab plus XELOX was restarted 5 weeks after surgery for another six cycles. Results: 43 patients (pts) with a median age of 66 years (38-80) were enrolled into this multicenter trial. 78% of these pts had synchronous disease, 51% started neoadjuvant treatment without primary tumor resection. The median number of metastases was 2 (1-1...